Benefit-Risk Assessment Using Number Needed to Treat and Number Needed to Harm for Time-to-Event Endpoints

被引:2
|
作者
Ke, Chunlei [1 ]
Jiang, Qi [1 ]
机构
[1] Amgen Inc, Global Biostat Sci, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA
来源
关键词
Additive hazards; Benefit-risk assessment; Clinical trial; Number needed to harm; Number needed to treat; ADDITIVE HAZARDS MODEL; NORMAL VARIABLES; FAILURE; RATIOS;
D O I
10.1080/19466315.2016.1197849
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Number needed to treat (NNT) is a useful measure to meaningfully translate the therapeutic effect of a drug to clinical practice. Time-to-event endpoints are commonly used in clinical trials. NNT has been extended to time-to-event endpoints, but these extensions have some limitations. In addition, NNT and number needed to harm (NNH) can be applied to provide useful information in support of benefit-risk assessment of a drug. In this article, we will first propose a hazard-based NNT using an additive hazards model. Estimation and inference procedures will be provided. Graphical methods and formal statistical tests will be proposed to evaluate the assumption of additivity. We will also discuss using NNT and NNH to facilitate benefit-risk decision making. Inference on the NNH and NNT ratio will be explored as well. The proposed methods will be illustrated with a real clinical trial dataset.
引用
收藏
页码:379 / 385
页数:7
相关论文
共 50 条
  • [1] Quantitative Benefit-Risk Assessment of Rosiglitazone: Number Needed to Treat, Number Needed to Harm and Likelihood to be Helped or Harmed
    Mendes, D.
    Alves, C.
    Batel-Marques, F.
    DRUG SAFETY, 2014, 37 (10) : 859 - 859
  • [2] Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
    Citrome, Leslie
    Del Rio, Margarita Sanchez
    Dong, Yan
    Nichols, Russell M.
    Tockhorn-Heidenreich, Antje
    Foster, Shonda A.
    Stauffer, Virginia L.
    ADVANCES IN THERAPY, 2021, 38 (08) : 4442 - 4460
  • [3] Number needed to treat in time-to-event studies
    Lopez-Briz, Eduardo
    Martinez-Lopez, Iciar
    Puigventos Latorre, Francesc
    Fraga Fuentes, M. Dolores
    MEDICINA CLINICA, 2014, 143 (10): : 472 - 473
  • [4] Benefit-Risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies
    Sacco, S.
    Lalla, A.
    Singh, R. B. Halker
    Holle-Lee, D.
    Pozo-Rosich, P.
    Nagy, K.
    Kelton, K.
    Piron, C.
    Gandhi, P.
    Ailani, J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [5] Number needed to treat for time-to-event data with competing risks
    Gouskov, Natalia A.
    Kundu, Suprateek
    Imrey, Peter B.
    Fine, Jason P.
    STATISTICS IN MEDICINE, 2014, 33 (02) : 181 - 192
  • [6] Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
    Leslie Citrome
    Margarita Sánchez del Rio
    Yan Dong
    Russell M. Nichols
    Antje Tockhorn-Heidenreich
    Shonda A. Foster
    Virginia L. Stauffer
    Advances in Therapy, 2021, 38 : 4442 - 4460
  • [7] NUMBER NEEDED TO TREAT (NNT) AND NUMBER NEEDED TO HARM (NNH)
    Osio Uribe, Oscar
    IATREIA, 2007, 20 (04) : 441 - 444
  • [8] Number needed to treat and number needed to harm: What are they good for?
    Citrome, Leslie
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2023, 68 : 105 - 107
  • [9] Number Needed to Treat and Number Needed to Harm: Its Importance
    Jassir Acosta, Maria Paula
    Gomez-Restrepo, Carlos
    UNIVERSITAS MEDICA, 2021, 62 (02):
  • [10] Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed
    Citrome, Leslie
    Ketter, Terence A.
    Cucchiaro, Josephine
    Loebel, Antony
    JOURNAL OF AFFECTIVE DISORDERS, 2014, 155 : 20 - 27